Lecap Asset Management Ltd. Invests $669,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Lecap Asset Management Ltd. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,433 shares of the biopharmaceutical company’s stock, valued at approximately $669,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC raised its stake in Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals in the second quarter worth $26,000. Altitude Crest Partners Inc. bought a new stake in Alnylam Pharmaceuticals during the first quarter valued at $30,000. Friedenthal Financial acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $51,000. Finally, Meeder Asset Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 1,237.5% in the 2nd quarter. Meeder Asset Management Inc. now owns 321 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 297 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ALNY has been the topic of a number of research reports. Bank of America increased their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Citigroup upped their price target on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Chardan Capital reissued a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Barclays lifted their price target on Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, TD Cowen lifted their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a research note on Monday. Six research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $290.86.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now owns 136 shares of the company’s stock, valued at approximately $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $20,563,480. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,398 shares of company stock worth $13,595,460 in the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Trading Down 0.4 %

Shares of ALNY stock opened at $293.69 on Friday. The stock’s fifty day simple moving average is $274.09 and its 200-day simple moving average is $220.55. The company has a market capitalization of $37.15 billion, a price-to-earnings ratio of -109.59 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 107.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.21) EPS. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.